和鉑醫藥-B(02142.HK):6月17日於公開市場購回股份,涉資近900萬港元
格隆匯6月18日丨和鉑醫藥-B(02142.HK)發佈公告,有關於市場上購回總額達2.4億港元的股份的計劃,考慮到現時交易價格水平低估了公司內在價值、業務前景或近期業務成果。於2025年6月17日,公司於公開市場購回股份,涉資近900萬港元,在2025年對於在香港聯交所上市的生物科技公司而言,屬重大購回金額。回購進度的加速體現了公司致力提升股東價值並對公司長遠增長前景充滿信心。公司可根據市場情況授權進一步購回計劃,惟須遵守當時適用的可用購回授權。
公司進一步指出,基於公司股份於2025年6月17日的收市價,(i)公司的市值除以於2025年新達成的合作項下約50億美元的預付款及潛在里程碑付款總額,僅爲0.16;及(ii)公司的市值除以集團所有合作項下約100億美元的潛在里程碑付款總額,僅爲0.08。公司認爲,目前的股份交易價格水平反映出公司內在價值及業務前景的低估,並重申將最大化股東價值的堅定承諾。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.